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Factors predicting pain and early
discontinuation of tumour necrosis factor-
α-inhibitors in people with rheumatoid
arthritis: results from the British society for
rheumatology biologics register
Daniel F. McWilliams1,2* and David A. Walsh1,2
Abstract
Background: We examined pain levels in 2 cohorts assembled from the British Society for Rheumatology Biologics
Register (BSRBR), and investigated which factors predicted Bodily Pain scores and discontinuation of TNFα-inhibitors.
Method: Data were retrieved from BSRBR-RA databases for up to 1 year after commencing TNFα-inhibitors (n =
11995) or being treated with non-biologic therapies (n = 3632). Bodily Pain scores were derived from the Short
Form-36 (SF36) questionnaire and norm-transformed to allow comparison with UK population averages.
Discontinuation data were from physician reports. Other data, including 28-joint disease activity score (DAS28)
measurements, were from clinical examination, interview, medical records and self-report questionnaires. DAS28-P
was derived as the proportion of DAS28 attributed to patient-reported factors (tender joint count and visual
analogue score). Missing baseline variables from both cohorts were imputed into 20 replicate datasets. Odds ratios
(OR) and adjusted OR were calculated for higher than median pain within each cohort.
Results: Participants reported moderate to severe pain at baseline, and pain scores remained >1SD worse than
normal population standards at 1 year, even when disease activity responded to treatment. Baseline pain was
associated with DAS28-P, worse physical function, worse mental health, and DAS28. After logistic regression,
independent predictors of higher than median pain at follow up were baseline Bodily Pain score, higher DAS28-P,
worse physical function or mental health and co-morbidities. Higher age, male gender, and higher BMI were
additional independent predictors of higher pain in participants who received TNFα-inhibitors. Baseline pain was
also one of the predictors of discontinuation of the first TNFα-inhibitor within 1 year, as were female gender,
current smoking, co-morbidities, extra-articular manifestations and worse function.
Conclusion: Pain persists in people with treated RA, even in those for whom inflammation responds to treatment.
Worse pain outcomes are predicted by factors different to those typically found to predict inflammatory disease
activity in other studies. Worse pain at baseline also predicts discontinuation of TNFα-inhibitors. Improved pain
management should complement inflammatory disease suppression in RA.
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Background
Treatment of rheumatoid arthritis (RA) with biologic or
non-biologic disease modifying anti-rheumatic drugs
(DMARDs) aims to control inflammation in order to re-
tain functional capacity into later life. People with RA
often name pain as one of the most unpleasant charac-
teristics of their condition [1, 2]. Although patient-
centred measures related to quality of life (QoL) improve
during treatments that suppress inflammation [3], pain
remains a problem for people with treated RA.
Inflammation is a cause of pain in RA, but other fac-
tors might also be important. Pain can persist even in
people who achieve remission of inflammatory disease
[4]. Previous studies have highlighted risk factors for
worse pain prognosis, such as low mood [5–7] and gen-
der [8]. We previously reported that in early RA, pain
was not readily predicted by classic RA risk factors and
severity measures [9]. Instead it was predicted by the
proportion of 28-joint disease activity score (DAS28)
contributed by the patient-reported components tender
joint count (TJC) and visual analogue score (VAS-GH)),
and we have proposed that a derived index, termed
DAS28-P, might be related to abnormal pain processing
[9, 10]. These factors that predict worse pain contrast
with those that predict inflammatory disease activity or
radiographic damage (recent literature reviews include
[11, 12]). Predictors of pain in RA resemble risk factors
that predict outcomes of other painful, chronic musculo-
skeletal conditions, such as low back pain [13]. Disease
activity assessment, using DAS28, may be importantly
confounded by pain [14, 15]. If non-inflammatory pain
mechanisms inflate DAS28, then pain management
strategies might be indicated rather than or in addition
to escalating anti-inflammatory treatment.
In this study, we aimed to measure relationships be-
tween pain and inflammatory disease activity, and to
identify baseline predictors of pain 1 year after commen-
cing either a new biologic or undergoing non-biologic
treatment in established RA. Continuation of biologic
therapy should, in part, be determined by satisfactory
symptomatic response and so we also measured associ-
ation between pain-related factors and discontinuation
of TNFα-inhibitors. We examined factors associated
with baseline pain, 1 year pain and 1 year discontinu-
ation of TNFα-inhibitors using data from 2 British Soci-
ety for Rheumatology Biologics Register (BSRBR)
cohorts of people with RA.
Methods
Data retrieval
Two biologic-naïve groups were assembled for analysis
from the British Society for Rheumatology-Biologics
Registry (BSRBR) national registry databases (University
of Manchester, UK. Cohorts ethical approval reference
number: MREC 00/8/53). The first was a hospital-based
UK cohort of people initiating treatment at baseline with
their first ever biologic agent. Participants were eligible
for this cohort if they commenced treatment at baseline
with one of 3 TNFα-inhibitors (infliximab, etanercept or
adalimumab). UK national guidelines recommend that
TNFα-inhibitors should be commenced after inadequate
response to 2 other non-biological DMARDs [16]. Data
from a total of 11995 people were supplied, of whom
92 % (11013) had baseline pain data and 68 % (8113)
had 1 year pain data available and (92 %) 10949 were eli-
gible for analysis of TNF-inhibitor discontinuation after
1 year. A second (non-biologic) cohort was hospital-
based and collected by the BSRBR-RA as a referent for
the BSRBR biologic cohort. Each participant was eligible
if they were biologic-naïve, and were starting or receiv-
ing only non-biologic therapies at baseline. We analysed
the BSRBR non-biologic cohort in its own right. The
BSRBR cohorts have provided high-quality longitu-
dinal data regarding disease activity, clinical character-
istics and QoL [17]. Analyses of the BSRBR-RA
cohorts have already provided data showing responses
to treatment [18–20], safety [21, 22] and prevalence
of co-morbidities [23].
Data from a total of 3632 people were supplied, of
whom 80 % (2916) had baseline pain data and 63 %
(2284) had 1 year pain data available. All participants
from both cohorts satisfied 1987 American College of
Rheumatology (ACR) classification criteria for RA [24].
Demographic and lifestyle data available at baseline in-
cluded age, gender, smoking history and body mass
index. RA disease data were seropositivity (positive or
negative for rheumatoid factor); the presence of erosions
(present or absent); physician-reported extra-articular
RA features, which we classified as present or absent;
DAS28 (TJC, swollen joint count (SJC), erythrocyte sedi-
mentation rate (ESR), C-reactive protein (CRP), VAS-
GH). The variables ESR, CRP and SJC were used as the
best estimates of current inflammation. Use of each
DMARD at the time of recruitment to the cohort was
recorded as present, absent or data unavailable (metho-
trexate, sulphasalazine, hydroxychloroquine, lefluno-
mide, azathioprine, gold salts, cyclophosphamide and
ciclosporin, plus steroid use were recorded). Other re-
lated clinical data were for co-morbidities, which in-
cluded physical and mental health conditions and we
classified as present or absent [23]; and self-report ques-
tionnaires addressing disability Health Assessment
Questionnaire (HAQ) [25, 26], or QoL (including bodily
pain); Short Form-36 (SF36) (Bodily Pain, Mental
Health, Vitality (fatigue) and Physical Function (disabil-
ity)) [27]. Baseline DAS28 and DAS28-P (the proportion
of DAS28 attributed to tender joint count and visual
analogue scale) were calculated as previously reported
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[9, 28]. DAS28-P is a ratio of the TJC and VAS-GH, after
weighting and transformation, divided by the DAS28-
ESR score, and is only calculated for active RA cases due
to loss of normality at low values of DAS28. The formula
used was ((0.56 * √TJC) + (0.014 * VAS-GH)) / DAS28-
ESR, for RA cases with DAS28-ESR ≥3.2 [9].
Study outcomes
Norm-based SF36-Bodily Pain subscale scores at 1 year
were used as the primary measure of pain outcome. This
used the semi-continuous SF36-Bodily Pain scores [27],
has been validated in RA populations [29], and yields a
score where the mean for the UK population is 50 with
a sd of 10. Use of norm-based data facilitates compari-
son between this study and the UK population [30]. The
pain items from the SF36 were “how much bodily pain
have you had during the past week?” and “During the
past week, how much did pain interfere with your nor-
mal work (including both work outside the home and
housework)?” SF36 version 2 was used for the data
collection.
Discontinuation of TNFα-inhibitors was used as a sur-
rogate outcome for treatment failure, and this analysis
was performed independently of the prediction of pain
outcome. TNFα-inhibitor use or discontinuation (plus
the reason for discontinuation) was reported by each
study centre at each data collection. Discontinuation was
defined as absence of the initial TNFα-inhibitor treat-
ment after baseline in a participant in the TNFα-
inhibitor cohort. Switching from the initial biologic drug
was taken as discontinuation, even if it was replaced by
another TNFα-inhibitor. Two important reasons for dis-
continuation, inefficacy (IE) and adverse event (AE),
were also analysed. Almost all (>99 %) of the partici-
pants that discontinued TNFα-inhibitor were using ei-
ther non-biologic DMARDs or glucocorticoids at 1 year
follow up. Data on any new biologics were not available
for this study.
Statistical analyses
Greater than median pain measures (at baseline or at
1 year) or 1 year discontinuation of TNF-inhibitors were
the primary outcomes. Mean (standard deviation) and
percentage prevalences of participant characteristics are
presented. Simple univariate comparisons between
groups used ANOVA (followed by pairwise testing with
a Bonferroni correction), t-tests or χ2 tests. Cohen’s d
statistic was calculated using the difference between
means over the pooled standard deviation of both time
points. Pain was stratified into bands delimited by the sd
of the UK population norm (10 points) and presented
graphically. ESR readings were divided into <23 for men
and <30 for women for secondary analyses [31].
To attempt to address some of the biases poten-
tially introduced by missing data, analyses using
multiple imputations of 20 datasets were performed
for baseline variables (age, gender, height, weight,
TJC, SJC, ESR, VAS-GH, HAQ, seropositive, smok-
ing, all SF36 variables at baseline). The follow up
pain outcome variable was not imputed. Fully condi-
tional specification methodology was used with con-
tinuous variables imputed using multiple linear
regression and categorical variables using multiple
logistic regression. Hosmer-Lemeshow χ2 and the
Nagelkerke pseudo-R2 were used to assess model fit
and model power respectively for complete case
data. Comparisons were made between cases with
complete data for all covariates and those where at
least one variable would require imputation.
Imputed data were used for the primary analyses.
The composite indices of DAS28 and DAS28-P were
calculated from measured or imputed ESR, SJC, TJC
and VAS-GH; whereas the BMI was imputed directly.
Imputed continuous variables were converted into ter-
tiles, or WHO BMI groups (<25, 25–30, ≥30 kg/m2).
These are described in Additional file 1: Table S1. For
associations with dichotomised outcome variables, the
odds ratios (OR) and 95 % confidence intervals (CI)
were calculated for the risk of above vs below median
pain score (at baseline or at 1 year) or 1 year discon-
tinuation. The univariate potential associations SF36-
Bodily Pain score and discontinuation were not ad-
justed for multiple comparisons.
Multivariable-adjusted logistic regression models
were generated, which yielded adjusted OR (aOR) and
95 % CI. The measures at baseline were used to in-
vestigate the baseline association with the pain out-
come, and also to predict 1 year pain (1 year change
in pain from baseline was also used so confirm find-
ings). In order to minimise collinearity, inclusion of
SF36 subscales was limited those with a priori
hypothesised associations with pain; mental health,
baseline pain, fatigue (SF36-vitality) and disability
(SF36-physical function). DAS28 was not strongly as-
sociated with DAS28-P (TNFα-inhibitor cohort: r =
0.19; non-biologic cohort r = 0.34), and therefore this
did not preclude inclusion of both within the same
statistical models.
Subgroups of the cohorts at the 1 year time point
were examined at the individual patient level to as-
sess pain reported by people considered as having a
good response to treatment or with low inflamma-
tion. These subgroups were either those that
achieved good EULAR response [32], those satisfying
remission criteria [33], those with both normal ESR
levels and a swollen joint count of zero, or those
who achieved CRP ≤5 g/L at 1 year.
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Statistical significance was taken when p < 0.05 or the
95 % CI did not encompass unity.
Results
The demographics of each cohort are shown in Table 1.
The non-biologic cohort had fewer females, was older,
had a shorter RA duration, and lower DAS28-P. The
non-biologic cohort also displayed milder disease, with
lower DAS28 and less impact on QoL than did the
TNFα-inhibitor cohort (p < 0.003 for each comparison).
Mean SF36-Bodily Pain scores at baseline were >2 s.d.
higher than the UK general population average, indicat-
ing moderate to severe pain. The respective median self-
report for TNF-inhibitor and non-biologic cohorts pain
levels were ‘severe’ and ‘moderate’; and the respective
interference that pain had on their normal work, includ-
ing housework, was ‘quite a bit’ and ‘moderately’. Bodily
Pain scores improved significantly after 6 months in
both cohorts, and these improvements were maintained
at 1 year (p < 0.001 for all comparisons) (Fig. 1a). The
improvements and Cohens d statistic for pain improve-
ment between baseline and year 1 was 0.91 for TNFα-
inhibitor cohort and 0.04 for non-biologic cohort. After
6 months of treatment, reported pain was comparable
between TNFα-inhibitor and non-biologic cohorts.
Mean Bodily Pain scores in both cohorts remained
>1 s.d. higher than the average for the UK population
after 1 year (Fig. 1a). After 1 year, The median self-
report for TNF-inhibitor and non-biologic cohorts pain
levels were both ‘moderate’; and the interference that
pain had on their normal work, including housework
were both ‘moderately’).
Further analyses examined whether persistent pain
was also evident in people in whom the inflammatory
component of their disease was well controlled at the
1 year time point. In the TNFα-inhibitor cohort, 6517,
6581, 6210 and 4341 participants provided data for 1 year
analysis of EULAR response; DAS28 < 2.6 remission;
normal levels for both ESR and swollen joints (0/28);
and measurements of CRP ≤5 g/L. Fifty four percent of
participants achieved moderate, and 29 % achieved good
EULAR responses. Seventeen percent achieved DAS28 <
2.6 remission. Twenty percent achieved normal levels
for both ESR and swollen joints. Thirty three percent
achieved CRP ≤5 g/L. Pain improved significantly after
1 year (Fig. 1a), in those with moderate and good
EULAR responses (Fig. 1c), for those in DAS28 remis-
sion (Fig. 1e) and for those with normal ESR and SJC at
1 year (Fig. 1g) (p < 0.001 for all comparisons). Despite
this improvement in pain, the SF36-Bodily Pain scores at
1 year indicated higher pain than UK population means
in each of these ‘well controlled’ subgroups (Figs. 1c, e,
g). Analysis of individual patient data at the 1 year time
point revealed that more than half of the participants in
Table 1 Baseline characteristics of the TNFα-inhibitor and non-
biologic cohorts at baseline
TNFα-inhibitor
cohort
Non-biologic
cohort
Non-imputed Non-imputed
N= 11995 3632
Age Years 56 (12) 60 (12)
Gender Female 76 % 73 %
Ethnicity White 96 % 98 %
BMI Kg.m−2 27.0 (7.1) 27.4 (6.6)
Smoking Current 22 % 24 %
Ex- 38 % 40 %
Never 40 % 37 %
DAS28 6.6 (1.0) 5.1 (1.3)
TJC 16 (7) 8 (7)
SJC 11 (6) 6 (5)
ESR 46 (29) 35 (25)
VAS-GH 73 (20) 55 (24)
DAS28-P 0.48 (0.07) 0.44 (0.10)
Duration of RA Years 13 (10) 10 (10)
Serology Positive 65 % 58 %
Erosions Yes 63 % 46 %
Extra-articular Yes 29 % 19 %
Comorbidity Yes 60 % 65 %
HAQ 2.0 (0.6) 1.5 (0.8)
SF36-Vitality 33 (10) 39 (10)
SF36-Mental
Health
40 (11) 45 (11)
SF36-Physical
function
16 (11) 24 (14)
SF36-Bodily Pain 25 (7) 31 (9)
Steroids at
baseline
44 % 23 %
DMARD at
baseline
Methotrexate 58 % 65 %
Sulphasalazine 15 % 32 %
Azathioprine 2 % 2 %
Leflunomide 8 % 12 %
D-penicillamine 1 % 1 %
Gold 2 % 5 %
Hydroxychloroquine 10 % 15 %
Ciclosporin 1 % 2 %
Cyclophosphamide 0.10 % 0.10 %
The baseline characteristics of participants are shown, at baseline with and
without imputation. Mean (sd) or percent are shown. The standard deviations
of the 20 imputed datasets are derived from the average sd of each
imputation. All SF36 scores are norm-based and may be compared to the UK
mean (sd) score of 50 (10), with lower scores indicating worse health. Serology
status was recorded as Rheumatoid Factor positive prior to, or at, baseline
ESR erythrocyte sedimentation rate, SJC swollen joint count, TJC tender joint
count, VAS-GH visual analogue scale-general health
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each ‘well controlled’ subgroup had SF36-Bodily Pain
scores >1 sd worse than the national average, that is a
normed SF36-Bodily Pain score of less than 40 (Figs. 1d,
f, h). Similar analysis was performed in the non-biologic
cohort, where available data indicated that 29 % (265/
905) achieved moderate, and 23 % (207/905) good
EULAR response criteria, and 18 % (155/909) achieved
DAS28 < 2.6 remission at 1 year. Of those with good
Fig. 1 Pain up to 1 year of follow up. a, c, e, g show mean (sd) of norm-based SF36-Bodily Pain Scores using all data available at each time point. The UK
population has an average norm-based score of 50 (grey, solid line), and lower scores indicate worse pain. b, d, f,) show the individual patient data from
the TNF-inhibitor cohort demonstrating the proportion of participants with pain levels stratified by the norm-based standard deviation of 10. a shows
mean (sd) of SF36-Bodily Pain scores from baseline to year 1. c, e and g show mean (sd) of norm based SF36-Bodily Pain scores at 1 year stratified by
treatment response using c EULAR criteria; e DAS28 remission; and g normal swollen joint count (SJC = 0) with normal ESR range. Panels b, d, f and h
show the stratification of individual patient data by SF36-Bodily Pain score in the TNF-inhibitor cohort at 1 year follow up. The cross-hatched, light shaded
portion represents “better than UK average SF36-Bodily Pain” (≥50) and darker shaded plain portions represent increasingly worse pain at 1 year (incre-
ments of 10, which is ~1 sd for norm based SF36 scores). b Proportions individual patients with increasing severity of SF36-Bodily Pain scores at 1 year
follow up; d stratified by EULAR response criteria, f stratified by DAS28 remission criteria, and h stratified into normal ESR and SJC ranges
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EULAR response or those in DAS28 remission, 58 or
50 % (respectively) showed 1 year SF36-Bodily Pain scores
>1 sd worse than national average (Figs. 1c and e).
After the characterisation and description of pain pro-
gression, further analysis focussed upon factors associ-
ated with pain. The variables at baseline with the
greatest percentage of missing values in the TNF-
inhibitor cohort were HAQ (7 %), ESR (8 %), DAS28-P
(9 %), DAS28-ESR (9 %), BMI (12 %) and SF36 subscales
(9 - 10 %). In the non-biologic cohort the greater per-
centages of missing values were found in HAQ (20 %),
ESR (11 %), DAS28-ESR (12 %), DAS28-P (18 %) and
SF36 subscales (19 - 20 %). In the TNFα-inhibitor and
non-biologic cohorts, DAS28-ESR was higher in the
complete cases than in cases with imputed 1 year values
(6.6 vs 6.4 and 5.3 vs 4.4 respectively), and SF36-Bodily
Pain scores indicated worse pain (25 vs 26 and 31 vs 33
respectively). Baseline SF36-Bodily Pain scores were ana-
lysed for all available data and were associated with
many baseline factors in each cohort (Table 2). The
baseline characteristics that predicted median SF36-
Bodily Pain scores indicating worse pain at 1 year were
similar between TNFα-inhibitor and non-biologic co-
horts in univariate analyses (Table 3). Baseline character-
istics of older age, higher BMI, current smoking, co-
morbidities, DAS28, DAS28-P, and worse mental health,
vitality, physical function and pain were positive predic-
tors of SF36-Bodily Pain scores indicating worse pain at
1 year in both cohorts (Table 3). SF36-Bodily Pain scores
indicating worse pain at 1 year were also predicted by
male gender and extra-articular disease at baseline in the
TNFα-inhibitor cohort, and by HAQ disability in the
non-biologic cohort. In both cohorts, methotrexate use
at baseline was associated with less pain at follow up,
whereas glucocortiocosteroids or leflunomide was each
associated with SF36-Bodily Pain scores indicating worse
pain at 1 year. The overall models were weak (TNFα-in-
hibitor cohort) or moderate (non-biologic cohort) in
explaining pain scores at 1 year (Nagelkerke pseudo-R2
= 0.16 and 0.32, respectively).
Logistic regression confirmed that higher DAS28-P,
worse mental health, physical function or pain at base-
line each independently predicted worse than median
SF36-Bodily Pain score indicating worse pain at 1 year
in each cohort (Table 4). For example, for DAS28-P at
baseline the adjusted odds ratio (95 % CI) for worse pain
at 1 year in the TNFα-inhibitor cohort was 1.14 (1.07–
1.21), p < 0.001 and in the non-biologic control cohort it
was 1.27 (1.11 – 1.46), p = 0.001. Pain was also predicted
by co-morbidities, male gender, higher BMI and current
smoking at baseline in the TNFα-inhibitor cohort; and
less vitality and lower function in the non-biologic co-
hort. A sensitivity analysis showed that the presence of
variables describing concurrent DMARD and steroid use
did not alter the main findings of the models. Two sec-
ondary analyses, to further assess whether persistent in-
flammation would explain the predictors of pain, were
performed in the participant subgroups in the TNF-
inhibitor cohort who achieved ESR levels <23 for men
and <30 for women, or CRP ≤5 g/L respectively after
1 year. A similar logistic regression analysis was per-
formed for each subgroup, adjusting for baseline pain
and potential confounding covariates. For the subgroup
who achieved a lower ESR at 1 year, predictors of 1 year
SF36-Bodily Pain scores indicating worse pain (aOR,
(95 % CI)) were worse baseline pain (1.50, (1.29 – 1.76)
p < 0.001), current smoking (1.45 (1.10 – 1.91, p = 0.008),
comorbidity (1.37 (1.08 – 1.73), p = 0.008), higher
DAS28-P (1.17 (1.01 – 1.34) p = 0.034), worse mental
health (1.36 (1.17 – 1.58) p < 0.001), worse physical func-
tion (1.80 (1.54 – 2.10) p < 0.001), higher BMI (1.16
(1.00 – 1.34) p = 0.043) while methotrexate at baseline
was negatively associated (0.63 (0.048 – 0.82) p = 0.001),
each of which was similar to our primary findings. Simi-
larly, for the subgroup who achieved CRP < 5 g/L at
1 year, SF36-Bodily Pain scores indicating worse pain
were independently predicted (aOR, 95 % CI) by baseline
current smoking (1.97, 1.26 – 3.07, p = 0.003) and higher
DAS28-P (1.26, 1.02 – 1.56, p = 0.030).
Discontinuation of the initial TNFα-inhibitor was re-
ported by 32 % (3475/10949) at 1 year. Of patients with
median SF36-Bodily Pain scores indicating worse pain at
1 year, 39 % (1302/3376) had discontinued their original
TNF inhibitor, as compared to 17 % (722/4140) of those
with less than median pain. Mean (s.d.) SF36-Bodily Pain
scores at 1 year were worse in those who stopped or
changed their TNFα-inhibitors (29 (9)) than in those
who continued (35 (10), p < 0.001). SF36-Bodily Pain
scores at 1 year were worse both in those who discontin-
ued TNFα-inhibitors due to inefficacy (28 (9)) and in
those who discontinued due to adverse events (29 (9)),
compared with those who continued (each p < 0.05).
Univariate predictors of discontinuation included higher
baseline DAS28, extra-articular disease, co-morbidities,
worse physical function, mental health, vitality and Bod-
ily Pain scores (Additional file 1: Table S2). Logistic re-
gression showed independent prediction of
discontinuation by baseline smoking, extra-articular dis-
ease, comorbidities, worse physical function and Bodily
Pain score at baseline, and baseline non-biologic treat-
ment (Table 5). People with a baseline treatment that
did not include methotrexate or sulphasalazine were
more likely to discontinue TNFα-inhibitors, whether due
to inefficacy or to adverse events. Shorter disease dur-
ation and higher pain at baseline were stronger predic-
tors of TNFα-inhibitor discontinuation due to inefficacy
rather than to adverse events, whereas age, poorer phys-
ical function, longer disease duration and extra-articular
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Table 2 Univariate associations with higher than median baseline SF36-Bodily Pain scores in TNFα-inhibitor and non-biologic cohorts
Tertile or group TNFα-inhibitor cohort Non-biologic cohort
Original Imputed (20 sets) p Original p Imputed (20 sets) p
Age Youngest (ref) 1 1 1 1
Mid 1.06 (0.97 - 1.17) 0.230 1.06 (0.97 - 1.16) 0.203 1.09 (0.91 - 1.30) 0.366 1.04 (0.89 - 1.22) 0.657
Oldest 0.98 (0.89 - 1.07) 0.621 0.99 (0.90 - 1.08) 0.815 1.05 (0.88 - 1.26) 0.617 0.97 (0.83 - 1.14) 0.746
Gender Male (ref) 1 1 1 1
Female 1.11 (1.01 - 1.21) 0.033 1.10 (1.01 - 1.20) 0.033 1.06 (0.90 - 1.25) 0.504 1.04 (0.90 - 1.20) 0.656
BMI <25 (ref) 1 1 1 1
25 to <30 1.00 (0.91 - 1.10) 0.961 1.01 (0.92 - 1.10) 0.877 1.06 (0.89 - 1.26) 0.534 1.02 (0.88 - 1.19) 0.816
≥30 1.23 (1.11 - 1.37) <0.001 1.22 (1.11 - 1.34) <0.001 1.56 (1.29 - 1.89) <0.001 1.44 (1.22 - 1.70) <0.001
Smoking Never (ref) 1 1 1 1
Ex 1.09 (1.00 - 1.19) 0.052 1.09 (1.00 - 1.18) 0.042 1.34 (1.14 - 1.58) 0.001 1.26 (1.08 - 1.46) 0.003
Current 1.20 (1.08 - 1.33) <0.001 1.19 (1.08 - 1.31) 0.001 1.58 (1.30 - 1.93) <0.001 1.54 (1.30 - 1.83) <0.001
DAS28 Lowest (ref) 1 1 1 1
Mid 1.49 (1.34 - 1.65) <0.001 1.49 (1.35 - 1.65) <0.001 2.00 (1.65 - 2.42) <0.001 2.03 (1.72 - 2.39) <0.001
Highest 2.94 (2.65 - 3.25) <0.001 2.91 (2.64 - 3.21) <0.001 4.26 (3.48 - 5.20) <0.001 3.99 (3.37 - 4.72) <0.001
DAS28-P Lowest (ref) 1 1 1 1
Mid 1.50 (1.36 - 1.66) <0.001 1.48 (1.35 - 1.63) <0.001 2.03 (1.67 - 2.48) <0.001 1.97 (1.67 - 2.33) <0.001
Highest 1.63 (1.47 - 1.80) <0.001 1.62 (1.47 - 1.78) <0.001 2.45 (2.00 - 2.99) <0.001 2.58 (2.17 - 3.05) <0.001
ESR Lowest (ref) 1 1 1 1
Mid 1.35 (1.22 - 1.50) <0.001 1.34 (1.22 - 1.47) <0.001 1.27 (1.05 - 1.53) 0.012 1.21 (1.03 - 1.42) 0.020
Highest 1.85 (1.68 - 2.05) <0.001 1.81 (1.65 - 1.99) <0.001 1.84 (1.52 - 2.22) <0.001 1.69 (1.44 - 1.98) <0.001
SJC Lowest (ref) 1 1 1 1
Mid 1.09 (0.98 - 1.20) 0.100 1.08 (0.98 - 1.18) 0.106 1.24 (1.03 - 1.48) 0.023 1.19 (1.01 - 1.40) 0.037
Highest 1.27 (1.16 - 1.40) <0.001 1.28 (1.17 - 1.40) <0.001 1.50 (1.26 - 1.79) <0.001 1.51 (1.29 - 1.76) <0.001
VAS-GH Lowest (ref) 1 1 1 1
Mid 1.81 (1.63 - 2.01) <0.001 1.83 (1.66 - 2.02) <0.001 2.64 (2.19 - 3.18) <0.001 2.66 (2.25 - 3.15) <0.001
Highest 5.21 (4.69 - 5.78) <0.001 4.89 (4.44 - 5.40) <0.001 5.45 (4.48 - 6.63) <0.001 5.28 (4.44 - 6.28) <0.001
TJC Lowest (ref) 1 1 1 1
Mid 1.35 (1.22 - 1.49) <0.001 1.34 (1.22 - 1.47) <0.001 1.55 (1.29 - 1.85) <0.001 1.63 (1.39 - 1.91) <0.001
Highest 1.91 (1.73 - 2.11) <0.001 1.91 (1.74 - 2.10) <0.001 3.13 (2.58 - 3.78) <0.001 3.01 (2.61 - 3.65) <0.001
Duration Shortest (ref) 1 1 1 1
Mid 0.98 (0.89 - 1.08) 0.696 0.99 (0.90 - 1.08) 0.799 1.25 (1.05 - 1.50) 0.015 1.15 (0.98 - 1.35) 0.088
Longest 1.03 (0.93 - 1.13) 0.612 1.03 (0.95 - 1.13) 0.479 1.34 (1.12 - 1.60) 0.002 1.25 (1.07 - 1.47) 0.006
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Table 2 Univariate associations with higher than median baseline SF36-Bodily Pain scores in TNFα-inhibitor and non-biologic cohorts (Continued)
Serology Seronegative (ref) 1 1 1 1
Seropositive 1.08 (0.99 - 1.17) 0.072 1.07 (0.99 - 1.16) 0.071 1.09 (0.94 - 1.26) 0.246 1.04 (0.91 - 1.19) 0.545
Erosions None (ref) 1 1 1 1
At baseline 0.97 (0.91 - 1.06) 0.426 0.97 (0.90 - 1.05) 0.450 1.01 (0.88 - 1.17) 0.882 0.99 (0.87 - 1.13) 0.947
Extra-articular
manifestation
No (ref) 1 1 1 1
Yes 1.16 (1.09 - 1.27) <0.001 1.16 (1.07 - 1.26) <0.001 1.16 (0.96 - 1.39) 0.120 1.18 (1.00 - 1.40) 0.053
Co-morbidity No (ref) 1 1 1 1
Yes 1.30 (1.19 - 1.38) <0.001 1.28 (1.19 - 1.38) <0.001 1.56 (1.34 - 1.81) <0.001 1.52 (1.32 - 1.74) <0.001
HAQ Lowest (ref) 1 1 1 1
Mid 0.98 (0.89 - 1.08) 0.682 0.99 (0.91 - 1.09) 0.870 5.04 (4.09 - 6.22) <0.001 4.55 (3.80 - 5.44) <0.001
Highest 1.10 (0.99 - 1.21) 0.068 1.05 (0.96 - 1.15) 0.329 19.44 (15.38 - 24.56) <0.001 16.30 (13.31 - 19.95) <0.001
SF36-Vitality Best (ref) 1 1 1 1
Mid 1.83 (1.64 - 2.05) <0.001 1.86 (1.68 - 2.06) <0.001 3.19 (2.61 - 3.90) <0.001 2.99 (2.51 - 3.56) <0.001
Worst 5.61 (5.05 - 6.22) <0.001 5.31 (4.82 - 5.86) <0.001 8.89 (7.25 - 10.89) <0.001 8.35 (6.97 - 10.00) <0.001
SF36-Mental Health Best (ref) 1 1 1 1
Mid 1.92 (1.73 - 2.14) <0.001 1.96 (1.78 - 2.17) <0.001 2.87 (2.37 - 3.48) <0.001 2.65 (2.24 - 3.12) <0.001
Worst 4.39 (3.98 - 4.85) <0.001 4.35 (3.96 - 4.78) <0.001 7.03 (5.71 - 8.67) <0.001 5.65 (4.75 - 6.71) <0.001
SF36-Physical Function Best (ref) 1 1 1 1
Mid 2.70 (2.41 - 3.01) <0.001 2.55 (2.29 - 2.81) <0.001 3.35 (2.75 - 4.09) <0.001 3.05 (2.56 - 3.64) <0.001
Worst 9.29 (8.32 - 10.38) <0.001 8.17 (7.38 - 9.05) <0.001 16.53 (13.13 - 20.81) <0.001 12.84 (10.60 - 15.56) <0.001
Steroids Not (ref) 1 1 1 1
At baseline 1.28 (1.17 - 1.39) <0.001 1.25 (1.16 - 1.35) <0.001 1.44 (1.21 - 1.71) <0.001 1.44 (1.23 - 1.68) <0.001
Methotrexate Not (ref) 1 1 1 1
At baseline 0.77 (0.71 - 0.84) <0.001 0.75 (0.69 - 0.82) <0.001 0.92 (0.79 - 1.07) 0.276 0.92 (0.80 - 1.05) 0.210
Sulphasalazine Not (ref) 1 1 1 1
At baseline 0.86 (0.77 - 0.96) 0.007 0.86 (0.78 - 0.96) 0.006 0.88 (0.75 - 1.03) 0.104 0.84 (0.73 - 0.96) 0.012
Lefunomide Not (ref) 1 1 1 1
At baseline 1.01 (0.88 - 1.17) 0.882 0.99 (0.86 - 1.14) 0.942 1.50 (1.20 - 1.87) <0.001 1.48 (1.21 - 1.80) <0.001
Azathioprine Not (ref) 1 1 1 1
At baseline 1.03 (0.79 - 1.35) 0.836 1.04 (0.80 - 1.34) 0.796 1.85 (1.12 - 3.08) 0.018 1.79 (1.12 - 2.86) 0.016
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Table 2 Univariate associations with higher than median baseline SF36-Bodily Pain scores in TNFα-inhibitor and non-biologic cohorts (Continued)
Hydroxychloroquine Not (ref) 1 1 1 1
At baseline 0.89 (0.78 - 1.02) 0.100 0.90 (0.79 - 1.02) 0.094 0.89 (0.73 - 1.09) 0.280 0.94 (0.78 - 1.13) 0.519
Gold Not (ref) 1 1 1 1
At baseline 1.06 (0.77 - 1.44) 0.750 1.01 (0.75 - 1.37) 0.941 1.77 (1.24 - 2.52) 0.002 1.62 (1.18 - 2.21) 0.002
Crude OR (95 % CI) for higher than median SF36-Bodily Pain score at baseline using pooled estimates from the 20 imputed datasets at baseline. The p values have not been adjusted for multiple comparisons. Continu-
ous variables divided into tertiles except for body mass index (BMI). For each variable, the highest tertile is that which signifies worst health (including SF36 variables, which have been reversed). Missing data percent-
ages >5 % for the cases with baseline SF36-Bodily Pain scores were found in the TNF-inhibitor cohort (HAQ(7 %), ESR (7 %), DAS28-ESR (8 %), DAS28-P (8 %), BMI (11 %)) and in the non-biologic cohort (ESR (10 %),
DAS28-ESR (11 %), DAS28-P (18 %), BMI (6 %))
ESR erythrocyte sedimentation rate, SJC swollen joint count, TJC tender joint count, VAS-GH visual analogue scale-general health. Significant results highlighted in bold
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Table 3 Univariate predictors of higher than median SF36-Bodily Pain scores after 1 year in TNFα-inhibitor and non-biologic cohorts
Tertile or group TNFα-inhibitor cohort Non-biologic cohort
Complete case Imputed Complete case Imputed
Crude OR (95 % CI) p Crude OR (95 % CI) p Crude OR (95 % CI) p Crude OR (95 % CI) p
Age Youngest (ref) 1 1 1 1
Mid 1.35 (1.21 – 1.51) <0.001 1.35 (1.21 – 1.51) <0.001 1.39 (1.13 - 1.71) 0.002 1.39 (1.13 - 1.71) 0.002
Oldest 1.67 (1.50 – 1.87) <0.001 1.67 (1.50 – 1.87) <0.001 1.41
(1.15 - 1.74)
0.001 1.41 (1.15 - 1.74) 0.001
Gender Male (ref) 1 1 1 1
Female 0.88 (0.79 – 0.98) 0.015 0.88 (0.79 – 0.98) 0.015 1.10 (0.91 - 1.33) 0.358 1.10 (0.91 - 1.33) 0.358
BMI <25 (ref) 1 1 1 1
25 to <30 1.24 (1.11 - 1.38) <0.001 1.22 (1.10 - 1.35) <0.001 1.12 (0.92 - 1.37) 0.264 1.12 (0.92 - 1.35) 0.276
≥30 1.53 (1.36 - 1.73) <0.001 1.48 (1.33 - 1.66) <0.001 1.61 (1.29 - 2.00) <0.001 1.60 (1.30 - 1.98) <0.001
Smoking Never (ref) 1 1 1 1
Ex 1.23 (1.11 - 1.36) <0.001 1.23 (1.12 - 1.36) <0.001 1.33 (1.12 - 1.59) 0.002 1.37 (1.14 - 1.65) 0.001
Current 1.39 (1.23 - 1.56) <0.001 1.39 (1.23 - 1.56) <0.001 1.24 (1.00 - 1.53) 0.054 1.24 (1.00 - 1.53) 0.054
DAS28 Lowest (ref) 1 1 1 1
Mid 1.20 (1.07 – 1.34) 0.002 1.20 (1.07 – 1.34) 0.002 1.29 (1.04 - 1.59) 0.021 1.31 (1.07 - 1.61) 0.010
Highest 1.64 (1.47 – 1.84) <0.001 1.64 (1.47 – 1.84) <0.001 1.96 (1.58 - 2.43) <0.001 1.95 (1.59 - 2.39) <0.001
DAS28-P Lowest (ref) 1 1 1 1
Mid 1.15 (1.03 – 1.29) 0.013 1.15 (1.03 – 1.29) 0.013 1.65 (1.32 - 2.07) <0.001 1.59 (1.28 - 1.97) <0.001
Highest 1.46 (1.30 – 1.63) <0.001 1.46 (1.30 – 1.63) <0.001 2.26 (1.80 - 2.85) <0.001 2.20 (1.77 - 2.73) <0.001
ESR Lowest (ref) 1 1 1 1
Mid 1.00 (0.90 - 1.12) 0.977 1.00 (0.90 - 1.12) 0.978 1.12 (0.91 - 1.38) 0.306 1.06 (0.87 - 1.30) 0.571
Highest 1.14 (1.02 – 1.27) 0.019 1.14 (1.03 - 1.27) 0.016 1.24 (1.00 - 1.54) 0.049 1.21 (0.99 - 1.48) 0.070
SJC Lowest (ref) 1 1 1 1
Mid 0.97 (0.87 – 1.08) 0.576 0.97 (0.87 – 1.08) 0.580 0.88 (0.71 - 1.09) 0.268 0.89 (0.73 - 1.10) 0.295
Highest 1.03 (0.93 - 1.14) 0.608 1.03 (0.93 - 1.14) 0.593 0.96 (0.78 - 1.15) 0.613 0.94 (0.77 - 1.14) 0.549
VAS-GH Lowest (ref) 1 1 1 1
Mid 1.28 (1.15 – 1.43) <0.001 1.27 (1.14 - 1.42) <0.001 1.82 (1.48 - 2.24) <0.001 1.81 (1.48 - 2.23) <0.001
Highest 1.84 (1.65 - 2.06) <0.001 1.84 (1.65 - 2.05) <0.001 2.83 (2.29 - 3.49) <0.001 2.82 (2.28 - 3.47) <0.001
TJC Lowest (ref) 1 1 1 1
Mid 1.12 (1.01 – 1.25) 0.040 1.12 (1.01 – 1.25) 0.037 1.54 (1.25 - 1.88) <0.001 1.52 (1.25 - 1.86) <0.001
Highest 1.42 (1.27 - 1.59) <0.001 1.42 (1.28 - 1.59) <0.001 2.11 (1.71 - 2.60) <0.001 2.08 (1.69 - 2.56) <0.001
Duration Shortest (ref) 1 1 1 1
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Table 3 Univariate predictors of higher than median SF36-Bodily Pain scores after 1 year in TNFα-inhibitor and non-biologic cohorts (Continued)
Mid 1.04 (0.93 – 1.16) 0.484 1.04 (0.93 – 1.16) 0.468 1.44 (1.17 - 1.77) 0.001 1.44 (1.17 - 1.77) 0.001
Longest 1.22 (1.09 – 1.35) <0.001 1.21 (1.09 - 1.35) <0.001 1.55 (1.27 - 1.91) <0.001 1.55 (1.26 - 1.90) <0.001
Serology Seronegative (ref) 1 1 1 1
Seropositive 0.98 (0.89 - 1.07) 0.657 0.98 (0.89 - 1.07) 0.674 1.05 (0.89 - 1.24) 0.578 1.05 (0.89 - 1.24) 0.608
Erosions None (ref) 1 1 1 1
At baseline 0.92 (0.84 – 1.01) 0.091 0.93 (0.85 - 1.01) 0.096 1.16 (0.98 - 1.37) 0.082 1.16 (0.98 - 1.37) 0.090
Extra-articular
manifestation
No (ref) 1 1 1 1
Yes 1.20 (1.09 – 1.32) <0.001 1.20 (1.09 – 1.32) <0.001 1.21 (0.99 - 1.49) 0.071 1.21 (0.99 - 1.49) 0.071
Co-morbidity No (ref) 1 1 1 1
Yes 1.66 (1.51 – 1.81) <0.001 1.66 (1.51 – 1.81) <0.001 1.82 (1.53 - 2.18) <0.001 1.82 (1.53 - 2.18) <0.001
HAQ Lowest (ref) 1 1 1 1
Mid 0.98 (0.87 - 1.09) 0.667 0.98 (0.88 - 1.09) 0.680 3.03 (2.40 - 3.83) <0.001 2.84 (2.28 - 3.54) <0.001
Highest 1.01 (0.90 - 1.13) 0.909 1.02 (0.91 - 1.13) 0.804 10.63 (8.25 - 13.70) <0.001 9.17 (7.23 - 11.62) <0.001
SF36-Vitality Best (ref) 1 1 1 1
Mid 1.23 (1.09 - 1.38) 0.001 1.21 (1.08 - 1.35) 0.001 2.40 (1.90 - 3.03) <0.001 2.29 (1.84 - 2.85) <0.001
Worst 1.90 (1.70 - 2.12) <0.001 1.84 (1.66 - 2.05) <0.001 5.40 (4.30 - 6.80) <0.001 4.87 (3.92 - 6.06) <0.001
SF36-Mental Health Best (ref) 1 1 1 1
Mid 1.69 (1.51 - 1.90) <0.001 1.66 (1.49 - 1.85) <0.001 2.08 (1.66 - 2.59) <0.001 2.26 (1.84 - 2.78) <0.001
Worst 2.40 (2.15 - 2.68) <0.001 2.29 (2.07 - 2.56) <0.001 4.26 (3.36 - 5.41) <0.001 3.90 (3.15 - 4.83) <0.001
SF36-Physical Function Best (ref) 1 1 1 1
Mid 2.01 (1.80 - 2.26) <0.001 1.95 (1.74 - 2.17) <0.001 3.29 (2.60 0 4.15) <0.001 2.70 (2.16 - 3.38) <0.001
Worst 3.83 (3.41 - 4.30) <0.001 3.62 (3.23 - 4.04) <0.001 9.55 (7.40 - 12.34) <0.001 7.72 (6.15 - 9.72) <0.001
Steroids Not (ref) 1 1 1 1
At baseline 1.58 (1.44 - 1.74) <0.001 1.58 (1.44 - 1.74) <0.001 1.61 (1.32 - 1.96) <0.001 1.61 (1.32 - 1.96) <0.001
Methotrexate Not (ref) 1 1 1 1
At baseline 0.63 (0.57 - 0.69) <0.001 0.63 (0.57 - 0.69) <0.001 0.79 (0.67 - 0.95) 0.010 0.79 (0.67 - 0.95) 0.010
Sulphasalazine Not (ref) 1 1 1 1
At baseline 0.69 (0.61 - 0.78) <0.001 0.69 (0.61 - 0.78) <0.001 0.85 (0.71 - 1.02) 0.076 0.85 (0.71 - 1.02) 0.076
Lefunomide Not (ref) 1 1 1 1
At baseline 1.26 (1.07 - 1.49) 0.006 1.26 (1.07 - 1.49) 0.006 1.66 (1.28 - 2.16) <0.001 1.66 (1.28 - 2.16) <0.001
Azathioprine Not (ref) 1 1 1 1
At baseline 1.44 (1.07 - 1.95) <0.001 1.44 (1.07 - 1.95) <0.001 2.63 (1.37 - 5.03) 0.004 2.63 (1.37 - 5.03) 0.004
Hydroxychloroquine Not (ref) 1 1 1 1
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Table 3 Univariate predictors of higher than median SF36-Bodily Pain scores after 1 year in TNFα-inhibitor and non-biologic cohorts (Continued)
At baseline 0.67 (0.57 - 0.78) <0.001 0.67 (0.57 - 0.78) <0.001 0.81 (0.64 - 1.03) 0.084 0.81 (0.64 - 1.03) 0.084
Gold Not (ref) 1 1 1 1
At baseline 1.24 (0.87 - 1.76) 0.273 1.24 (0.87 - 1.76) 0.273 1.50 (1.02 - 2.20) 0.047 1.50 (1.02 - 2.20) 0.047
Odds ratios (95 % CI) for risk of higher than median pain at 1 year using original data and also pooled estimates of the 20 imputed datasets of baseline variables. The p values have not been adjusted for multiple
comparisons. Continuous variables divided into tertiles except for body mass index (BMI). For each variable, the highest tertile is that which signifies worst health (including SF36 variables, which have been reversed).
Missing data percentages >5 % for those cases with 1 year pain data available were found in the TNF-inhibitor cohort for HAQ (7 %), ESR (7 %), DAS28-ESR (8 %), DAS28-P (8 %), BMI (11 %), SF36 subscales (5 – 7 %);
and in the non-biologic cohort for HAQ (9 %), ESR (10 %), DAS28-ESR (11 %), DAS28-P (19 %), BMI 5 %) and SF36 subscales (8 % - 9 %))
ESR erythrocyte sedimentation rate, SJC swollen joint count, TJC tender joint count, VAS-GH visual analogue scale-general health. Significant results highlighted in bold
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Table 4 Multivariable-adjusted logistic regression for predictors of higher than median SF36-Bodily Pain scores after 1 year in TNFα-inhibitor and non-biologic cohorts
Higher than median pain score - 1 year
Variable at baseline Tertile or
group at
baseline
TNFα-inhibitors cohort Non-biologic cohort
Complete case Imputed Complete case Imputed
aOR (95 % CI) p aOR (95 % CI) p aOR (95 % CI) p aOR (95 % CI) p
Age Tertiles 1.14 (1.06 - 1.22) 0.001 1.19 (1.12 - 1.27) <0.001 1.06 (0.90 - 1.25) 0.470 1.03 (0.89 - 1.18) 0.728
Gender Female 0.84 (0.73 - 0.96) 0.013 0.84 (0.74 - 0.94) 0.003 0.86 (0.65 - 1.14) 0.296 0.90 (0.71 - 1.15) 0.317
BMI WHO groups 1.12 (1.05 - 1.21) 0.002 1.13 (1.05 - 1.21) 0.001 1.06 (0.91 - 1.24) 0.463 1.07 (0.93 - 1.22) 0.353
Smoking Current 1.25 (1.07 - 1.46) 0.006 1.28 (1.11 - 1.47) <0.001 0.98 (0.70 - 1.38) 0.924 1.16 (0.87 - 1.54) 0.317
Smoking Ex- 1.03 (0.90 - 1.17) 0.678 1.05 (0.94 - 1.17) 0.421 1.14 (0.87 - 1.49) 0.344 1.16 (0.92 - 1.46) 0.698
DAS28 Tertiles 1.02 (0.95 - 1.10) 0.638 1.01 (0.95 - 1.08) 0.640 0.80 (0.68 - 0.94) 0.007 0.86 (0.75 - 0.99) 0.041
DAS28-P Tertiles 1.13 (1.05 - 1.21) 0.001 1.14 (1.07 - 1.21) <0.001 1.26 (1.08 - 1.47) 0.003 1.27 (1.11 - 1.46) 0.001
Duration Tertiles 1.04 (0.97 - 1.12) 0.264 1.01 (0.95 - 1.08) 0.660 1.08 (0.92 - 1.27) 0.326 1.08 (0.94 - 1.24) 0.265
Serology Positive 0.91 (0.81 - 1.03) 0.127 0.96 (0.86 - 1.07) 0.440 1.01 (0.79 - 1.30) 0.919 1.04 (0.84 - 1.29) 0.696
Erosions Positive 0.93 (0.82 - 1.05) 0.244 0.94 (0.85 - 1.05) 0.282 0.98 (0.75 - 1.27) 0.848 1.02 (0.82 - 1.28) 0.838
Extra-articular
manifestation
Yes 1.09 (0.96 - 1.23) 0.191 1.06 (0.95 - 1.18) 0.305 1.03 (0.77 - 1.39) 0.840 0.95 (0.74 - 1.22) 0.698
Co-morbidity Yes 1.27 (1.12 - 1.43) <0.001 1.29 (1.16 - 1.43) <0.001 1.31 (1.01 - 1.70) 0.041 1.24 (1.00 - 1.55) 0.055
HAQ Tertiles 0.98 (0.91 - 1.05) 0.553 0.99 (0.93 - 1.05) 0.703 1.44 (1.17 - 1.78) <0.001 1.55 (1.29 - 1.87) <0.001
SF36-Vitality Tertiles 0.95 (0.88 1.03) 0.183 0.97 (0.91 - 1.04) 0.382 1.31 (1.10 - 1.55) 0.002 1.21 (1.04 - 1.40) 0.015
SF36-Mental Health Tertiles 1.25 (1.17 - 1.35) <0.001 1.23 (1.15 - 1.31) <0.001 1.29 (1.08 - 1.53) 0.005 1.29 (1.11 - 1.50) 0.001
SF36-Physical Function Tertiles 1.51 (1.40 - 1.63) <0.001 1.47 (1.37 - 1.57) <0.001 1.44 (1.18 - 1.76) <0.001 1.36 (1.14 - 1.62) <0.001
SF36-Bodily Pain Tertiles 1.49 (1.38 - 1.62) <0.001 1.46 (1.36 - 1.57) <0.001 1.99 (1.64 - 2.42) <0.001 1.77 (1.49 - 2.10) <0.001
Steroid At baseline 1.24 (1.09 - 1.40) 0.001 1.28 (1.15 - 1.43) <0.001 1.25 (0.94 - 1.67) 0.124 1.35 (1.06 - 1.73) 0.016
Methotrexate At baseline 0.80 (0.71 - 0.91) 0.001 0.81 (0.72 - 0.92) <0.001 0.84 (0.61 - 1.14) 0.250 0.91 (0.70 - 1.19) 0.508
Sulphasalazine At baseline 0.80 (0.68 - 0.94) 0.008 0.81 (0.70 - 0.93) 0.003 0.87 (0.65 - 1.16) 0.337 0.98 (0.76 - 1.25) 0.845
Lefunomide At baseline 1.18 (0.97 - 1.44) 0.107 1.20 (1.01 - 1.43) 0.038 1.13 (0.73 - 1.74) 0.595 1.18 (0.81 - 1.71) 0.394
Azathioprine At baseline 1.40 (1.02 - 1.93) 0.036 1.18 (0.89 - 1.56) 0.245 1.26 (0.49 - 3.24) 0.637 1.87 (0.83 - 4.19) 0.131
Hydroxychloroquine At baseline 0.83 (0.68 - 1.01) 0.061 0.83 (0.70 - 0.99) 0.034 0.82 (0.59 - 1.15) 0.248 0.90 (0.68 - 1.20) 0.473
Gold At baseline 0.93 (0.65 - 1.31) 0.664 1.03 (0.75 - 1.40) 0.858 1.20 (0.69 - 2.07) 0.523 1.22 (0.75 - 1.99) 0.428
Two multi-variable adjusted logistic regression models for higher than median pain score at 1 year follow up using data from the 20 imputed datasets of baseline variables. Continuous variables divided into tertiles ex-
cept for body mass index (BMI). For each variable, the highest tertile is that which signifies worst health (including SF36 variables, which have been reversed). Significant results are highlighted in bold
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Table 5 Logistic regression for discontinuation of TNFα-inhibitors within 1 year of their initiation
Discontinuation of TNFα-inhibitors
Variable at
baseline
Tertile or
group at
baseline
All reasons Lack of Efficacy Adverse Drug Reaction
Complete case Imputed Complete case Imputed Complete case Imputed
aOR (95 % CI) p aOR (95 % CI) p aOR (95 % CI) p aOR (95 % CI) p aOR (95 % CI) p aOR (95 % CI) p
Age Tertiles 1.03 (0.96 - 1.10) 0.384 1.04 (0.98 - 1.11) 0.155 0.99 (0.90 - 1.09) 0.856 1.02 (0.94 - 1.11) 0.643 1.07 (0.98 - 1.17) 0.149 1.10 (1.02 - 1.19) 0.020
Gender Female 1.12 (0.99 - 1.27) 0.062 1.16 (1.04 - 1.28) 0.007 1.18 (0.99 - 1.40) 0.063 1.18 (1.02 - 1.37) 0.029 1.11 (0.94 - 1.32) 0.212 1.14 (0.99 - 1.32) 0.077
BMI WHO 0.99 (0.93 - 1.05) 0.673 0.98 (0.93 - 1.04) 0.538 1.03 (0.94 - 1.12) 0.540 1.01 (0.93 - 1.09) 0.826 0.94 (0.86 - 1.03) 0.173 0.94 (0.87 - 1.02) 0.141
Smoking Current 1.24 (1.09 - 1.42) 0.002 1.23 (1.09 - 1.38) 0.001 1.25 (1.04 - 1.50) 0.017 1.21 (1.03 - 1.43) 0.019 1.23 (1.02 - 1.47) 0.031 1.19 (1.02 - 1.40) 0.033
Smoking Ex 1.07 (0.96 - 1.21) 0.237 1.08 (0.98 - 1.20) 0.101 1.02 (0.87 - 1.21) 0.791 1.05 (0.91 - 1.21) 0.489 1.12 (0.96 - 1.32) 0.151 1.13 (0.99 - 1.30) 0.081
DAS28 Tertiles 1.04 (0.98 - 1.11) 0.226 1.02 (0.96 - 1.07) 0.580 1.08 (0.99 - 1.19) 0.087 1.04 (0.97 - 1.13) 0.285 1.02 (0.93 - 1.11) 0.711 0.99 (0.91 - 1.07) 0.738
DAS28-P Tertiles 0.99 (0.93 - 1.05) 0.719 0.98 (0.93 - 1.04) 0.567 0.96 (0.88 - 1.05) 0.410 0.98 (0.91 - 1.06) 0.549 0.99 (0.91 - 1.08) 0.876 1.00 (0.93 - 1.08) 0.993
Duration Tertiles 0.98 (0.92 - 1.05) 0.626 1.01 (0.95 - 1.06) 0.841 0.87 (0.79 - 0.95) 0.002 0.89 (0.82 - 0.96) 0.004 1.09 (1.00 - 1.19) 0.053 1.09 (1.01 - 1.17) 0.037
Serology Positive 1.04 (0.93 - 1.16) 0.523 1.01 (0.92 - 1.11) 0.830 0.94 (0.81 - 1.09) 0.432 0.92 (0.81 - 1.05) 0.213 1.09 (0.93 - 1.26) 0.283 1.07 (0.94 - 1.21) 0.344
Erosions Positive 0.93 (0.84 - 1.04) 0.224 0.93 (0.85 - 1.03) 0.151 0.96 (0.83 - 1.12) 0.619 0.95 (0.84 - 1.09) 0.482 0.93 (0.80 - 1.09) 0.368 0.94 (0.82 - 1.07) 0.324
Extra-articular
manifestation
Yes 1.17 (1.05 - 1.31) 0.004 1.17 (1.07 - 1.29) 0.001 1.08 (0.93 - 1.27) 0.302 1.06 (0.93 - 1.22) 0.386 1.33 (1.15 - 1.53) <0.001 1.32 (1.16 - 1.50) <0.001
Co-morbidity Yes 1.11 (1.00 - 1.24) 0.059 1.14 (1.04 - 1.25) 0.005 1.12 (0.97 - 1.31) 0.129 1.15 (1.01 - 1.31) 0.040 1.11 (0.95 - 1.28) 0.182 1.13 (1.00 - 1.28) 0.058
HAQ Tertiles 0.95 (0.89 - 1.01) 0.097 0.97 (0.92 - 1.02) 0.277 0.94 (0.86 - 1.02) 0.143 0.95 (0.88 - 1.03) 0.185 0.94 (0.86 - 1.02) 0.138 0.97 (0.90 - 1.05) 0.444
SF36-Vitality Tertiles 0.99 (0.92 - 1.06) 0.771 0.98 (0.92 - 1.04) 0.471 1.06 (0.96 - 1.17) 0.248 1.05 (0.96 - 1.14) 0.306 0.96 (0.87 - 1.06) 0.402 0.96 (0.89 - 1.04) 0.304
SF36-Mental
Health
Tertiles 1.02 (0.96 - 1.10) 0.531 1.02 (0.96 - 1.08) 0.540 1.00 (0.91 - 1.09) 0.923 1.00 (0.91 - 1.08) 0.900 1.02 (0.94 - 1.12) 0.608 1.02 (0.94 - 1.11) 0.587
SF36-Physical
Function
Tertiles 1.14 (1.06 - 1.22) <0.001 1.15 (1.08 - 1.22) <0.001 1.07 (0.97 - 1.18) 0.171 1.08 (0.99 - 1.18) 0.082 1.25 (1.14 - 1.38) <0.001 1.24 (1.14 - 1.35) <0.001
SF36-Bodily
Pain
Tertiles 1.13 (1.05 - 1.22) 0.002 1.12 (1.05 - 1.20) <0.001 1.23 (1.10 - 1.36) <0.001 1.22 (1.11 - 1.33) <0.001 0.99 (0.90 - 1.10) 0.885 1.04 (0.95 - 1.14) 0.389
Steroid At baseline 0.99 (0.88 - 1.11) 0.796 0.96 (0.87 - 1.06) 0.436 0.98 (0.83 - 1.15) 0.777 0.93 (0.80 - 1.07) 0.288 0.96 (0.81 - 1.13) 0.613 0.94 (0.82 - 1.09) 0.380
Methotrexate At baseline 0.69 (0.61 - 0.78) <0.001 0.70 (0.63 - 0.78) <0.001 0.73 (0.61 - 0.87) <0.001 0.70 (0.60 - 0.82) <0.001 0.60 (0.50 - 0.71) <0.001 0.58 (0.50 - 0.67) <0.001
Sulphasalazine At baseline 0.74 (0.63 - 0.86) <0.001 0.74 (0.65 - 0.84) <0.001 0.85 (0.69 - 1.04) 0.111 0.81 (0.68 - 0.97) 0.024 0.61 (0.49 - 0.77) <0.001 0.66 (0.55 - 0.80) <0.001
Lefunomide At baseline 1.07 (0.88 - 1.30) 0.524 1.01 (0.85 - 1.19) 0.928 1.36 (1.05 - 1.75) 0.019 1.19 (0.95 - 1.49) 0.133 0.86 (0.65 - 1.13) 0.267 0.88 (0.69 - 1.11) 0.262
Hydroxychloroquine At baseline 0.82 (0.68 - 0.98) 0.032 0.85 (0.73 - 1.00) 0.046 0.87 (0.67 - 1.12) 0.273 0.90 (0.73 - 1.13) 0.364 0.79 (0.61 - 1.04) 0.134 0.88 (0.71 - 1.10) 0.274
Gold At baseline 0.62 (0.41 - 0.95) 0.026 0.70 (0.48 - 1.01) 0.055 0.60 (0.32 - 1.10) 0.097 0.68 (0.40 - 1.16) 0.161 0.65 (0.37 - 1.14) 0.613 0.66 (0.40 - 1.11) 0.115
Three multi-variable adjusted logistic regression models for TNFα-inhibitor discontinuation at 1 year using data from 20 imputed datasets at baseline (table contains all variables included in the models). Continuous
variables divided into tertiles except for body mass index (BMI). For each variable, the highest tertile is that which signifies worst health (including SF36 variables, which have been reversed). Significant results are
highlighted in bold
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disease were stronger predictors of discontinuation due
to adverse events rather than inefficacy (Table 5). The
main model showed a weak effect for predicting discon-
tinuation for any cause (inefficacy or adverse events)
(Hosmer-Lemeshow χ2 = 3.1, p = 0.925; and the Nagelk-
erke pseudo-R2 = 0.04).
Discussion
In this study we found that pain persists in many people
with RA, despite the initial clinically significant [34] im-
provement upon commencing a TNFα-inhibitor. Several
baseline factors, including a high contribution of patient
reported factors to disease activity scores (high DAS28-
P), poor mental health, poor physical function and the
presence of co-morbidities, predicted pain outcomes
after either TNFα-inhibitors or traditional DMARDs.
Discontinuation of TNFα-inhibitors within 1 year from
their initiation was associated with persistent pain, and
predicted by baseline factors that overlapped with pre-
dictors of 1 year pain outcomes, including smoking, and
higher baseline pain.
We identified a broad range of demographic and clin-
ical factors that predicted 1 year pain outcomes in this
study. However, teasing apart inflammatory and non-
inflammatory pain mechanisms in the clinic can be ex-
tremely difficult. Although all 4 components of DAS28
are related to inflammation, the TJC and VAS-GH have
also been associated with non-inflammatory pain mecha-
nisms and concurrent fibromyalgia [10]. Derived indices
such as DAS28-P might provide insight into the balance
of different pain mechanisms. In a previous study of
people with early RA commencing non-biologic
DMARDs we found that higher DAS28-P scores pre-
dicted less improvement in pain at 12 months [9]. Early
RA differs from established disease in several important
aspects, such as the establishment of chronic inflamma-
tion and psychological adaptions to chronic pain, plus
the effects of new DMARD treatments on DMARD-
naïve patients. The current analysis of data from the
BSRBR confirms and extends to established disease our
findings in early RA, showing that high baseline DAS28-
P was also associated with worse pain after commencing
TNFα-inhibitors. High DAS28-P might be an indicator
that pain is driven by non-inflammatory mechanisms
such as central pain processing, resulting in dispropor-
tionately high tender joint counts and VAS-GH [10, 14,
15]. DAS28-P might be higher in people with fibromyal-
gia, either with [15] or without [14] RA, and was associ-
ated with widespread sensitivity to pressure induced
pain, even at sites distant to inflamed joints in people
with longstanding RA and DAS28 > 3.1 [10]. These ob-
servations are consistent with DAS28-P representing an
index of augmented pain processing in RA, which might
have utility for epidemiology studies where more
detailed pain measurements cannot be obtained, and in
retrospective studies or secondary data analysis. Target-
ing inflammatory pain mechanisms alone, either with
TNFα-inhibitors or traditional DMARDs, may be insuffi-
cient to adequately manage pain in these patients.
Other baseline factors that consistently predicted 1 year
pain outcomes were poor mental health, poor physical
function and the presence of co-morbidities. Poor men-
tal health predicts worse pain prognosis in a range of
chronic conditions [35]. Fear and low mood represent
emotional components of the pain experience, and
might impair uptake or response to treatment [36]. Fur-
thermore, psychological factors might specifically inter-
act with central pain processing to augment or maintain
chronic pain [5]. Physiotherapy and some exercise re-
gimes can improve outcomes [37, 38], and our data raise
the possibility that poor physical function may be a bar-
rier to responding to treatments. Prediction of poor pain
outcomes by baseline physical function was observed in
both cohorts, but was particularly strong in the non-
biologic DMARD cohort, and when physical function
was measured by SF36 rather than HAQ. Differences be-
tween data from the 2 questionnaires might reflect their
different emphases on mobility (SF36) or hand function
(HAQ). We found that the presence of comorbidities
predicted poorer pain prognosis. Osteoarthritis is a pos-
sible additional source of pain in those with RA and
might be prevalent in the aged population. Further work
could investigate whether comorbidities are a source of
pain, or have been barriers to effective RA treatment.
Poor mental health, physical function and comorbidities
might each be amenable to treatment in their own right,
but randomised clinical trials would be required to test
whether targeting them can improve pain. Gender was
found to predict future pain in our previous study of
early RA using similar methodologies to this one [9].
This association may be due to reporting preferences,
different pain sensitivities or different manifestations of
RA across the genders. We found no association be-
tween baseline erosions and future pain but more de-
tailed assessment would be required to determine
whether pain in RA might be partly mediated by pro-
gressive joint damage.
We have found that factors that predicted early dis-
continuation of TNFα-inhibitors only partially over-
lapped with those that predicted poor pain outcomes.
Pain levels were higher at baseline and at 1 year in those
who discontinued TNFα-inhibitors, suggesting that inad-
equate pain control contributes to some of the decisions
involved in discontinuation. We were not able to exclude
in this study the possibility that worse pain outcomes
might be caused by TNFα-inhibitor discontinuation, and
pain might further improve if more effective biologic
therapy were initiated. However, our secondary analysis
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on those with low CRP levels and those in remission
suggests that persistent inflammation was not the sole
reason for worse pain during follow up. The decision to
discontinue medication is based upon the balance be-
tween efficacy and adverse events, and so discontinu-
ation is often difficult to exclusively assign to one or
other reason. However, in the current study, pain pre-
dicted discontinuation due to inefficacy, and not due to
adverse events. We cannot be certain from our study of
any causal relationship between pain and TNFα-
inhibitor discontinuation, and further research would be
required to determine whether more effective analgesic
strategies would facilitate continuation of concurrently
administered TNFα-inhibitors.
Several factors limit interpretation of our findings. We
have identified baseline factors that predict 1 year pain
outcomes in people with RA, but further research is re-
quired to determine what interventions can improve on
these outcomes. Chanelling bias might have contributed
to observed associations between baseline non-DMARD
biologic medication use and 1 year pain, such that medi-
cations should not be interpreted as representing inde-
pendent risk factors. Exploration of the effects of
treatments upon RA pain is best addressed through ran-
domised controlled trials, although it was important to
include DMARD treatment in our models to ensure that
they did not confound our results. Patient choice to use
analgesics is moderated by a wide range of factors in
addition to pain severity, including efficacy, adverse
events and beliefs about medications and illness [39].
Further research would be required, therefore, to deter-
mine whether factors found in the current study to pre-
dict pain also predict healthcare utilisation due to that
pain. Our models predicting 1 year pain were based
upon an outcome variable (SF36 Bodily Pain score) with
a moderate percentage of missingness due to attrition.
The use of multiple imputation reduced the total level of
missingness in this study, but might have selected from
subsets of our data showing some degree of bias. Our
models had only weak to moderate effects in explaining
pain outcomes, and unmeasured factors might make im-
portant contributions to predicting Bodily Pain scores.
In particular, measurements of centrally-augmented
pain, or fibromyalgia classification criteria or a pain
Manikin, would also have been useful to verify our find-
ings. DAS28-P was associated with fibromyalgia classifi-
cation in a study of 50 people with RA [10], but data
were not available to determine fibromyalgia status in
the BSRBR cohorts. Even though the BSRBR cohorts are
large, un-measured factors, such as gene polymorphisms
or additional treatment details, could have mediated or
obscured associations between baseline characteristics
and pain outcomes. The search for additional risk factors
for worse pain or predictive markers requires further
work. Similarities between our findings in the BSRBR
and early RA [9] cohorts suggest that they might be gen-
eralisable to some other RA populations. Participants in
the TNFα-inhibitor cohort are likely to be representative
of patients commenced on their first biologic agent in
the UK, but caution should be exercised before general-
ising our findings. Further work should determine
whether the factors that we identified predict longer
term outcomes. Our findings suggest possible mecha-
nisms of pain but this study is not sufficient to justify
stratification of treatment based on these factors alone.
Conclusions
In conclusion, pain persists in many people with treated
RA, even when inflammation responds to treatment.
Worse 1 year pain outcomes are predicted by factors dif-
ferent to those typically found to predict inflammatory
disease activity, and include baseline Bodily Pain scores,
the proportion of DAS28 attributable to patient-reported
components, worse physical function or mental health,
and co-morbidities. Worse pain at baseline also predicts
TNFα-inhibitor discontinuation within 1 year. Improved
pain management should complement inflammatory dis-
ease suppression in RA.
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